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Encephalitis  is  a  common  clinical  problem  affecting  5  cases  per  100  000  population  annually.  After
exclusion of the usual infective causes, a number of cases remain unexplained. It has been observed that
many such cases have an autoimmune basis resulting in disruption of synaptic and ion channel function.
This diagnosis should be suspected based on subacute onset, short term memory loss, altered mental
status or psychiatric symptoms in combination with new focal neurological deficits, new onset seizures, CSF
pleocytosis  or  MRI  features  suggestive  of  encephalitis.  As  this  is  a  treatable  condition,  with  a  good
prognosis if recognised early, it is important not to miss the diagnosis.
BACKGROUND AND HISTORY
The term encephalitis refers to a rapidly progressive encephalopathy (usually in less than 6 weeks) as a
result of brain inflammation and has an estimated annual incidence of 5 cases per 100 000 population in a
UK cohort.[22, 72] This clinical scenario is quite rightly, in the first instance, considered to have an infectious
cause as any delay in the diagnosis and treatment is associated with a high morbidity and mortality. For
example, a more than two day delay in treatment initiation of Herpes simplex encephalitis results in a three-
fold worse outcome at 6 months.[62] In approximately 50% of cases, the aetiology remains undetermined but
with increased awareness many cases previously labelled as idiopathic encephalitis are now being identified
to  have  an  autoimmune  origin.[47,  77]  In  view  of  the  initial  presentation,  many  of  these  patients  are
mistakenly thought to have a psychiatric disorder resulting in a delay in treatment.
The first description of paraneoplastic limbic encephalitis was in 1968 in association with lung, breast and
thyroid  malignancies.[9]  These  patients  had  paraneoplastic  anti-Hu  or  anti-Ma2  antibodies:  intracellular
antibodies that result in irreversible, cytotoxic T cell responses with a poor prognosis and poor response to
therapy. In 2005 Ances et al described 8 patients with limbic encephalitis who, at that time, had unidentified
antibodies to neuronal surface proteins.[3] There has since been continued discovery of 1-2 such antibodies
per year.[51] These antibodies reversibly disrupt synaptic functions and ion channels and are thus responsive
to immunotherapy.[3] Unlike the intracellular neuronal antibodies, these neuronal cell surface antibodies have
a more  variable  association with  underlying malignancy (Table  1).  In  addition,  autoimmune encephalitis
affects patients of all age groups and detection has diagnostic, prognostic and therapeutic importance.
In this review, we discuss the clinical presentation of two of the most common autoimmune encephalopathies
supported with case studies. We suggest a practical diagnostic approach to these patients.
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Hu [1, 23] Limbic encephalitis* 28-82 (63) 75% male >95% SCLC









































46-77(60) 90% male 20-50% Thymoma
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16-77 (62) 50% male 50% SCLC
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*Limbic  encephalitis:  subacute  confusion,  memory  disturbance,  neuropsychiatric  features  and  seizures. 
†Morvan’s  syndrome:  cognitive  symptoms  or  seizures,  peripheral  nerve  hyperexcitability  and  insomnia  
Abbreviations: AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CASPR2, contactin-
associated protein-like  2;  DR2,  dopamine receptor  2;  DPPX,  dipeptidyl-peptidase-like  protein-6;  GABAR,
gamma-amino-butyric acid receptor; GAD,glutamic acid decarboxylase; IgLON5, immunoglobulin-like family
member 5; LGI1, leucine-rich, glioma-inactivated 1; mGluR5, metabotropic glutamate receptor 5; NMDAR, N-
methyl-D-aspartic acid receptor; PERM, progressive encephalomyelitis with rigidity and myoclonus.
METHODS
Relevant articles were identified through PubMed searches of articles published in English up to 1 May 2017.
Search terms included (alone or in combination) encephalitis, encephalopathy, limbic or autoimmune, which
yielded 358 results. Additional articles were identified in references. Priority was given to large case series.
Written consent was obtained from patients described in the case reports.
Anti-NMDA Receptor Encephalitis
This disorder is associated with IgG antibodies against the GluN1 subunit of N-methyl D-aspartate (NMDA)
receptors.[20] In vitro studies have shown that antibodies bind to NMDA receptors resulting in cross-linking
and internalization. The degree of damage correlates with antibody titres and reverses with antibody removal.
[31]
NMDA encephalitis has been found to be a common cause of encephalitis and the most common form of
autoimmune encephalitis.[13] In an English series,  4% of  patients with encephalitis  were diagnosed with
NMDA encephalitis.[21] The California encephalitis cohort identified NMDA encephalitis as being the most
common cause of  encephalitis,  4 times more common than viral causes, although this cohort was likely
influenced by referral bias.[18] An intriguing finding is that in some patients herpes simplex encephalitis may
also trigger other autoimmune reactions such as NMDA encephalitis.[15, 27]
The earliest reports of  NMDA encephalitis were in 2005 and 2007 when Vitaliani and Dalmau described
young women with ovarian teratomas presenting with psychiatric abnormalities, movement disorders and
central hypoventilation.[14, 76] These descriptions resulted in rapid identification of increasing numbers of
cases, with more than 600 cases being described in the literature by 2013.[68] The clinical presentation and
association with an underlying tumour varies with age and gender. The median age of presentation is 21
years but has ranged from 8 months to 81 years. Eighty one percent of the patients are female. Associated
tumours are present in 38% of patients, predominantly in females between the ages of 12 and 45. Males are
more likely to present below the age of 12 or over 45. Ninety seven percent of the associated tumours occur
in females, 94% of which are ovarian teratomas. The remainder of tumours are extraovarian teratomas, lung,
breast, testicular, ovarian, thymic and pancreatic in origin.[68]
These patients typically present in a step wise manner, although steps may occur in any order, all steps do
not have to be present and seizures can occur at any stage of disease. In 70% of patients a prodrome may
precede the onset of  other symptoms by up to 2 weeks.  Prodromal symptoms include headache, fever,
nausea, diarrhoea or features of an upper respiratory tract infection. Psychiatric symptoms occur next and
range from anxiety and insomnia to mania, paranoia, hallucinations and grandiose delusions.[32, 63] In some
patients psychiatric symptoms may predominate, resulting in psychiatric admission.[61] Atypical features for
schizophrenia,  such  as  pronounced  catatonia  or  associated  movement  disorders  and  seizures,  should
therefore prompt psychiatrists to exclude an underlying autoimmune encephalitis.[70] Short term memory
loss is common. Subsequent symptoms include movement disorders, autonomic dysfunction and central
hypoventilation. The range of movement disorders is vast including chorea, dystonia, oro-lingual dyskinesias
and  opisthotonic  posturing.  The  presence  of  autonomic  dysfunction  and  central  hypoventilation  often
necessitates ventilation and support in an intensive care setting.[32, 63] Monosymptomatic presentations are
very rare in all age groups but males more commonly present with partial seizures.[57, 73] Even though the
presenting symptoms may vary by age, within 4 weeks the majority of patients have developed a similar
cluster of symptomatology.[68]
Patients  with  long-term  psychiatric  diagnoses  have  on  occasion  been  found  to  have  NMDA  receptor
antibodies. The majority of  these patients do not have other symptoms described in the syndrome. It  is
important to note in these patients have IgA or IgM and not IgG antibodies, or antibodies against the GluN2
subunit, and not GluN1 subunit that has been associated with NMDA encephalitis. [6, 28, 41] Four percent of
patients have been described to have an overlapping,  concurrent or sequential demyelinating syndrome,
sometimes with associated Aquaporin 4 antibodies.[67]
With treatment 53% of patients improve within 4 weeks and 80% at 24 months. Symptoms often resolve in
the reverse  order  in  which they presented.  First  line treatment  consists  of  tumour removal  (if  present),
steroids, intravenous immunoglobulins and plasmapharesis. Up to 40% of patients do not respond to first line
therapy. Second line therapy consists  of  rituximab or  cyclophosphamide (individually or  in combination).
Approximately 80% of patients who fail first line therapy have a good outcome at 24 months after second line
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therapy. [68] It is important to keep in mind though that even after improvement of the acute episode there
may be persistent  deficits in memory, executive function and behavioural  disturbances.  The condition is
associated with a 7% mortality rate and relapses occur in 12-20%. Relapses may be separated from the
initial event by months to years, consist of only part of the initial syndrome and are usually less severe than
the initial episode.[17, 68] Relapses are also more likely to occur if the presenting episode was not treated or
undertreated.[35] Although relapses are less common in those who were treated for an underlying tumour, in
the case of a relapse patients should be re-assessed for presence of underlying contralateral or recurrent
teratoma.[32]
Case Report: NMDA Encephalitis (in a box)
A previously well 19 year old woman was referred to the neurology unit for investigation of a change in her
mental state. Five days prior to presentation she reported hearing unfamiliar voices while studying and feeling
suspicious of others. Two days later she stopped responding to those around her and subsequently had two
generalised tonic clonic seizures. There was no viral prodrome. On examination she was unresponsive to any
stimuli  and had prominent oromandibular dyskinesias,  dystonia and opisthotonic posturing.  She required
intubation, ventilation and ICU admission. While in ICU she had episodes of supraventricular tachycardia.
The patient was commenced on IVI acyclovir and investigated for an encephalitis. The FBC and metabolic
panels were normal, HIV ELISA negative and RPR non-reactive. A lumbar puncture showed 8 lymphocytes, 0
polymorphonuclear  cells,  protein  0.16  g/l,  glucose  4.4  mmol/l  (plasma  7  mmol/l).  The  CSF  FTA  and
cryptococcal latex agglutination test were negative, as were the PCR assays for HSV, VZV and CMV. NMDA
receptor  antibodies were  negative in  the serum but  positive  in  CSF.  The EEG was in  keeping with  an
encephalopathic state with an extreme delta brush pattern. MRI brain was normal. Pelvic ultrasound did not
show  an  underlying  ovarian  teratoma.  The  patient  did  not  respond  to  first  line  therapy  with  IV
methylprednisone, intravenous immunoglobulins or plasma exchange. She subsequently improved after 5
doses of IV cyclophosphamide. After a three-month admission to ICU she was stepped down to a general
ward. She was discharged home two months later with continued outpatient rehabilitation. The patient was
continued  on  oral  prednisone  and  azathioprine  and  has  continued  to  improve.  One  year  later  she  is
considering resuming her postgraduate studies.
Voltage-Gated Potassium Channel Antibodies
Voltage-gated  potassium  channels  (VGKC)  form  part  a  multiprotein  neuronal  complex.  Prior  to  2010
antibodies to the Kv1.1 and Kv1.2 subunits of the Shaker family of VGKC were recognised in association with
limbic  encephalitis,  faciobrachial  dystonic  seizures,  Morvan  syndrome  and  neuromyotonia.[33,  66,  74]
Subsequently it  has been identified that contactin-associated protein-2 (Caspr2)  and leucine-rich,  glioma
inactivated 1 protein (LGI1) are the true target antigens, each with unique clinical presentations.[34, 43, 71]
References to VGKC encephalitis prior to 2010 was most likely referring to an encephalitis secondary to LGI1
antibodies. Antibodies to other extracellular domains of the VGKC are not pathogenic and do not require
treatment with immunotherapy.[49]
LGI1 Antibodies
LGI1  is  a  protein  that  interacts  with  the  pre-synaptic  ADAM23 and  post-synaptic  ADAM22  and  AMPA
receptors, forming a trans-synaptic complex.  It  is  postulated that the antibodies result  in reduced AMPA
inhibitory behaviour, therefore resulting in neuronal hyperexcitability.[58]
LGI1 antibodies result in the second most common form of autoimmune encephalitis, after NMDA.[52] The
disorder has a male predominance, with a 2:1 male:female ratio and a median age at presentation of 63
years.[34,  36]  The  typical  presentation  is  that  of  faciobrachial  dystonic  seizures  affecting  the  arm  and
ipsilateral face, which may precede the onset of limbic encephalitis by up to 26 days.[36] These seizures last
about 3 seconds each and may occur a median of 50 times per day. Identification of the disorder at this stage
is  important  as  early  treatment  may prevent  the  rest  of  syndrome  from  developing  and  improves  the
prognosis.[38] Limbic encephalitis then develops, which consists of subacute onset confusion, short-term
memory disturbance and personality changes.[34] Patients may then go on to develop generalised tonic
clonic  seizures,  focal  seizures  with  impaired  awareness  of  temporal  lobe  origin  or  focal  seizures  with
associated  piloerection.[34,  74,  79]  Presentation  in  non-convulsive  status  is  not  uncommon.  As  these
seizures  do  not  respond  to  anticonvulsants  but  to  immunosuppressive  therapy the  identification  of  the
disorder is very important.[36] A unique feature of LGI1 encephalitis is hyponatraemia, which occurs in 60-
88% of  cases.  This  is  thought  to  be  due  to  LGI1  antibodies  binding  to  antidiuretic  hormone-secreting
neurones.[37] In the majority of patients, there is no tumour association. Prognostically, 71% of patients are
seizure free with monthly IV MTP but only 33% had normalization of memory.[54] Rapid identification and
treatment  of  this  disorder  is  important  as  a  delay in  institution  of  immunotherapy has  been associated
hippocampal  atrophy and poorer  long-term  memory outcome.[16]  Therefore,  despite  patients  with  LGI1
encephalitis having a more rapid response to treatment than those with NMDA encephalitis it is likely that
they have a poorer long-term recovery.[51] Reported mortality is 6% and relapses occur in 15%.[34, 43]
Caspr2 Antibodies
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Disease associated with Caspr2 antibodies is more diverse, consisting of  central and peripheral nervous
system involvement. Limbic encephalitis (42%) and Morvan syndrome (29%) are the most frequent clinical
syndromes and develop over an average of  4 months.[71] Morvan syndrome refers to a combination of
cognitive  symptoms  or  seizures,  peripheral  nerve  hyperexcitability  and  insomnia.  This  condition  occurs
predominantly in males with a median age of  66, 20% of  which have associated thymomas.[37, 71, 75]
Although these patients show a good response to immunotherapy relapses occur in 25%.[45, 71]
Case Report: LGI1 Encephalitis (in a box)
A 65 year old man with a background history of diabetes and hypertension presented in April 2014 with a first
episode generalised tonic clonic seizure lasting 10 minutes. He had no further neurological complaints and a
normal neurological examination. He also had features of a right middle lobe pneumonia and cholangitis. The
serum Na was 117 mmol/L with a urinary Na of 75 mEq/L, urine osmolality of 536 mOsm/kg and serum
osmolality  of  269  mOsm/kg.  This  was  interpreted  as  syndrome  of  inappropriate  ADH on  the  basis  of
underlying septicaemia, complicated by a seizure. A CT brain was normal. The underlying septicaemia was
treated and he was commenced on fludrocortisone tablets and water restriction. The patient was readmitted
in  June  with  further  seizures  and  persistent  hyponatraemia.  His  EEG  was  in  keeping  with  a  mildly
encephalopathic state. A lumbar puncture was performed and showed 0 polymorphs, 24 lymphocytes, protein
0.54 mg/dL, glucose 3.7 mmol/L (serum 6) and was negative for oligoclonal bands. The CSF FTA, HSV,
VZV, mumps and enteroviruses were negative. He was discharged on a higher dose of sodium valproate. In
July he was admitted to ICU in status epilepticus necessitating administration of anaesthetic agents. As part
of  treatment  of  refractory  status  epilepticus  he  also  received  IVI  methylprednisone,  intravenous
immunoglobulin and was discharged on 3 anticonvulsant agents. His MRI showed bilateral T2 and FLAIR
medial temporal lobe and right frontal lobe hyperintensities. On review in August his wife reported events
which consisted of head and eye turning to the right, twitching of the right side of his face as well as dystonic
posturing of the right arm. There were 3 or more episodes per hour, each lasting a few seconds to a minute.
His wife also reported a 4 month decline in his short-term memory and hypersomnolence. The patient was
subsequently tested  for  LGI1  antibodies,  which  were  positive  in  the  serum.  A  CT  chest  and  abdomen
excluded  underlying  malignancy.  The  patient  was  commenced  on  oral  prednisone  at  60mg  daily  and
azathioprine  150mg  daily.  There  was  subsequent  resolution  of  his  faciobrachial  dystonic  seizures,
normalisation of serum Na and improvement in his mental state. Eighteen months later the patient remains
well.
Diagnostic Evaluation
An encephalitis should be suspected in any patient presenting with combinations of subacute onset (in the
last  3 months)  of  confusion,  behavioural  change,  change in mood or  seizures.  Initially,  a viral  cause is
presumed and treatment  should  be commenced pending results  of  initial  investigations (Table  2).[72]  It
should be kept in mind that despite high assay sensitivity and specificity, CSF HSV PCR may be falsely
negative  if  performed  in  the  first  24  hours  of  the  illness  and should  therefore  be  repeated  if  clinically
suspected.[78]
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The majority of patients with autoimmune encephalitis have an abnormal lumbar puncture, with the exception
being patients with LGI1 antibodies (normal in 59%).[39, 51] The most common findings are pleocytosis of
less than 100 cells per L in 80%, mild-moderate increase of  CSF protein in 30% and the presence of
oligoclonal bands in 60%.[51]
The EEG is abnormal in most patients, and usually shows slow frontal or temporal activity, with or without
associated epileptiform discharges.[40] Although the EEG is a useful test to rule out alternative causes of
encephalopathy the only antibody specific finding is that of the extreme delta brush pattern in 30% of patients
with NMDA receptor encephalitis.[64]
Typical MRI findings include T2/FLAIR hyperintensities in one or both medial temporal lobes (Fig. 1). These
findings are however not specific, and may also occur in herpes encephalitis and in seizures of temporal lobe
onset.[50, 59] Similarly, a normal MRI doesn’t exclude the diagnosis, as it may be normal in 66% with NMDA
encephalitis [68] and 46% with LGI1 encephalitis.[36] However, even in patients with normal appearing MRI
scans, medial temporal lobe hypermetabolism has been identified on FDG-PET imaging.[4, 30]
Due to the overlap in symptomatology, antibody testing is available as a commercial panel that includes
antibodies  against  Caspr2,  LGI1,  NMDA,  AMPA  and  GABAb.  Testing  against  other  antibodies  is  only
performed in research laboratories. Detection of CSF antibodies to cell surface antigens strongly supports the
diagnosis whilst the significance of antibodies in serum only has less clear significance.[60] In a study looking
at paired CSF and serum samples in NMDA encephalitis, up to 14% of cases were serum negative but CSF
positive. Findings in serum alone have been described in LGI1, CASPR2, GlyR and GABAa. These are most
often  unreproducible  and  have  uncertain  disease  relevance,  suggesting  false  positive  results.[51]  IgG
antibodies are pathogenic but this cannot be generalised to IgA and IgM antibodies, which may be present in
healthy people.[10]
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Therefore, when testing for neuronal surface antibodies it is advisable to do so in both the CSF and serum for
a number of reasons: 
1. CSF analysis should be performed to exclude an infectious aetiology such as HSV. 
2. Fourteen percent of patients with NMDA encephalitis have antibodies in the CSF only. Percentages
in other encephalitides are unknown.[26] 
3. Uncertainty arises regarding clinical applicability of results in settings where serum antibodies are
positive but the CSF was not tested. 
4. There is better correlation in clinical course/prognosis between titers in CSF than in serum. However,
clinical correlation and not isolated monitoring of titers is advised as the antibodies may remain positive for
years after clinical recovery.[2, 29]
As early treatment improves outcome,[3, 7, 74] there has been a recent shift in guidelines towards earlier
recognition and treatment of autoimmune encephalitides.[25] These guidelines are less dependent on results
of antibody tests, as these may be negative in 10%, may not be accessible in all instances or may take weeks
to obtain.[24] Despite these limitations the identification of specific antibodies still has value as a prognostic
tool, guides the search for associated tumours and provides a definitive diagnosis.
In cases with a strong clinical suspicion of autoimmune encephalitis repeat testing of both CSF and serum
samples should be performed as the finding of delayed seropositivity has been described.[65] Therapy with
intravenous immunoglobulin may make result in false negative results, but this finding is less common in the
CSF  than  serum.  It  is  however  suggested  that  in  cases  where  patients  fulfil  the  criteria  for  probable
autoimmune encephalitis, and other causes have been excluded, treatment should be offered regardless of
antibody status.[25]
Possible autoimmune encephalitis should be suspected based on the presence of the following three criteria:
[25] (put in a box) 
1. Subacute  onset  (within  the  last  3  months)  of  short  term  memory  loss,  altered  mental  status
(personality change, lethargy or altered level of consciousness) or psychiatric symptoms 
2. At least one of: 
 a. new focal neurological deficits 
 b. new onset seizures 
 c. CSF pleocytosis (white cell count of more than 5 cells/mm3) 
 d. MRI features suggestive of encephalitis 
3.  Exclusion of other causes
Therefore in the presence of  these features,  and the exclusion of  abnormalities in the initial evaluation,
patients should be referred for further neurological workup and management.
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Figure 1: MRI findings in limbic encephalitis
T" FL AIR axial and coronal images showing medial temporal lobe hyperintensity
Treatment
Intracellular, paraneoplastic autoimmune encephalitides, with anti-Hu/Ma-2 or GAD antibodies are managed
by treatment  of  the underlying malignancy.  The response to therapy and prognosis  in  these patients is
generally poor due to the irreversible T cell driven cytotoxicity.[44] In those with antibodies to cell surface
antigens, however it  has been established that early treatment with immunomodulatory therapy improves
outcome, and may halt progression of the syndrome.[7, 36, 74] Published experience in treatment of NMDA
and LGI1 encephalitis has largely determined the treatment approach in these patients.[34, 43, 68] There are
however no specific guidelines for the treatment of autoimmune encephalitis, nor therapies that specifically
target antibodies. Based on experience first line therapy consists of tumour removal (if indicated), steroids,
intravenous immunoglobulins or plasma exchange. Patients who have a tumour have a worse outcome and
more relapses if  not  resected.[32]  If  there is  no response within 4 weeks  therapy may be escalated to
rituximab or cyclophosphamide. There has been a recent move towards the earlier use (or first line use) of
second line therapy as this may result in a lower relapse rate with good tolerability.[68] The rationale is that
these  agents  target  antibody production  by plasmablasts  rather  than  neutralising  or  eliminating  already
formed systemic antibodies.[53] It is currently unknown how long treatment should be continued for patients
with these disorders, thus individualised patient care decisions should be made.
Ongoing multidisciplinary care is of utmost importance in these patients and team members will vary during
the disease course. It is important to note that these are disorders requiring high degrees of therapeutic
commitment as average length of hospital admission is 3 months (NMDA encephalitis) with a longer period of
rehabilitation  thereafter.[51]  It  is  therefore  necessary  to  assemble  a  personalised  team  of  specialists
potentially  consisting  of  neurologists,  intensivists,  neuropsychologists,  psychiatrists  and  rehabilitation
personnel in order to optimise patient outcome.[56]
Tumour Screening
Unlike encephalitides with  antibodies against  intracellular  proteins (anti-Hu/Ma2),  the association with an
underlying malignancy is variable in patients with neuronal cell  surface antibodies.  The need for tumour
screening should therefore be guided by the identified antibody together with the neurological syndrome, age
and gender of  the patient (see table 1). Syndromes with a low likelihood of  associated malignancy may
therefore not justify ongoing evaluation. In cases with high tumour associations however, if initial screening is
negative repeat this should be repeated after 3-6 months and then 6 monthly for up to 4 years. Appropriate
screening  modalities  for  the  thorax  are  a  CT  chest  followed  by  FDG/PET,  breast  screening  with  a
mammogram and screening for ovarian tumours with a transvaginal ultrasound followed by a CT pelvis.
Screening with tumour markers alone is not reliable. [69]
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CONCLUSION
With  increased  awareness  autoimmune  encephalitis  has  become  one  of  the  most  frequent  causes  of
encephalitis.  This  is  a  treatable  condition  affecting  all  age  groups,  and  at  times  preferentially  young
individuals. Despite the poor prognosis in cases where diagnosis is delayed, with treatment a good outcome
can be expected in 70-80% of individuals.[47] Thus, an increased awareness with prompt identification and
treatment of these patients is paramount.
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